TP53BP1 and triple-negative breast carcinoma: Since 53BP1 expression is frequently lost in BRCA1/2-mutated or triple-negative breast cancers [58], it is thought that 53BP1 could be used as a biomarker for predicting the response of BRCA-mutated cancers to PARP inhibitor therapy.